Bristol-Myers Boosted By Opdivo Sales, Growth Prospects
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb Co.'s Opdivo (nivolumab) exceeded expectations in the third quarter and the company's commentary on future indications and combinations for the immunotherapy gave investors hope that sales would continue to blast ahead of Merck & Co.'s competing PD-1 inhibitor Keytruda (pembrolizumab).